Literature DB >> 8818658

Deletion mapping of chromosome 2 in human lung carcinoma.

T Otsuka1, T Kohno, M Mori, M Noguchi, S Hirohashi, J Yokota.   

Abstract

Sixty-three non-small cell lung carcinomas (NSCLCs) and 20 small cell lung carcinomas (SCLCs) were examined for loss of heterozygosity (LOH) on chromosome 2. Fifteen highly polymorphic dinucleotide markers spanning both the short and long arms of chromosome 2 were selected for a polymerase chain reaction (PCR)-based fine mapping. They included a DNA marker localized in the homozygously deleted region at 2q33, which we previously identified in an SCLC cell line. LOH on chromosome arm 2q was detected in 23/63 (37%) of NSCLC and 6/20 (30%) of SCLC, while LOH on 2p was observed in 14/56 (25%) and 4/17 (24%), respectively. There were two commonly deleted regions mapped to 2q32-q37 and 2p16-pter, and the homozygously deleted region at 2q33 was in the commonly deleted region on 2q. In NSCLC, the incidence of LOH on 2p and 2q was significantly higher in brain metastases than in primary tumors (P = 0.005 and 0.001, respectively). In addition, LOH on chromosome arm 2q occurred more frequently in moderately/poorly differentiated tumors than in well-differentiated tumors (P = 0.046). These results suggested that inactivation of tumor suppressor genes on chromosome 2 is involved in the phenotypic alterations of NSCLC cells into more aggressive ones.

Entities:  

Mesh:

Year:  1996        PMID: 8818658     DOI: 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.

Authors:  Su Man Lee; Jae Yong Park; Dong Sun Kim
Journal:  Mol Cells       Date:  2012-07-18       Impact factor: 5.034

2.  Amplification and deletion of the RAPH1 gene in breast cancer patients.

Authors:  Meire S Batistela; Dellyana R Boberg; Fabiana A Andrade; Michelli Pecharki; Enilze M de S F Ribeiro; Iglenir J Cavalli; Rubens S Lima; Cícero A Urban; Lupe Furtado-Alle; Ricardo L R Souza
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

Review 3.  Pathobiology of brain metastases.

Authors:  N Nathoo; A Chahlavi; G H Barnett; S A Toms
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

4.  Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain.

Authors:  A H Swirnoff; E D Apel; J Svaren; B R Sevetson; D B Zimonjic; N C Popescu; J Milbrandt
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

5.  Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity.

Authors:  Mei Xu; Aaron J Knox; Katherine A Michaelis; Katja Kiseljak-Vassiliades; Bette K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2012-05-04       Impact factor: 4.736

6.  DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.

Authors:  M Suzuki; H Shigematsu; D S Shames; N Sunaga; T Takahashi; N Shivapurkar; T Iizasa; E P Frenkel; J D Minna; T Fujisawa; A F Gazdar
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

7.  Methylation-Sensitive Melt Curve Analysis of the Reprimo Gene Methylation in Gastric Cancer.

Authors:  Hanze Wang; Yansong Zheng; Junzhong Lai; Qianping Luo; Huican Ke; Qi Chen
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

8.  Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR.

Authors:  Stefanie Moritz; Matthias Krause; Jessica Schlatter; Nils Cordes; Anne Vehlow
Journal:  Cancers (Basel)       Date:  2021-10-24       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.